Nearly 23 million people across the EU5 suffer from major depressive disorder. Generic availability of a growing number of therapies has improved patient access to antidepressants and loosened restrictions on off-label adjunctive use of atypical antipsychotics. New branded therapies will face increasing market access challenges as they compete for positioning in this crowded market. Clear demonstration of improved efficacy over standard-of-care comparators is necessary, though in some markets, safety or quality of life improvements are acceptable when accompanied by noninferior efficacy, and successfully targeting subpopulations or unmet treatment needs are additional keys to therapies securing favorable formulary placement and reimbursement terms.
- Unipolar Depression - Access & Reimbursement - Detailed, Expanded Analysis (EU5)
Author(s): Angela Sparrow, Ph.D.
Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain.
Dr. Sparrow holds a Ph.D. in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.